Media

INTAS launches THYMOTAS - a patented, powerful immuno-booster add-on to standard COVID-19 treatment

INTAS Develops COVID-19 Hyperimmune Globulin - A New Treatment

Intas Pharmaceuticals becomes the first to launch Romiplostim in India, revolutionizing chronic immune thrombocytopenia (ITP) therapy.

Binish Chudgar wins Ernst & Young "Entrepreneur of the Year 2018" award in Lifesciences and Healthcare category

Intas is the Most Recognised Company At The Global Generics & Biosimilar Awards 2018

Intas’ Pelgraz® (Pegfilgrastim) Given Green Light By CHMP

INTAS launches THYMOTAS - a patented, powerful immuno-booster add-on to standard COVID-19 treatment.

Binish Chudgar wins Ernst & Young "Entrepreneur of the Year 2018" award in Lifesciences and Healthcare category

Intas pharmaceuticals to be the first to launch pegfilgrastim biosimilars in europe

Intas Pharmaceuticals acquires the generics business of Actavis in the UK & Ireland

Intas lowers cancer treatment cost by 60%

Intas becomes the first Indian company to launch Biosimilar in the EU

Intas acquires Hospital Business in Spain and Portugal

Intas launches Azacitidine molecule in India

Intas completes sale of ChrysCapital's stake to Temasek

Intas launches rituximab


company-logo
Corporate Office

Corporate House, Near Sola Bridge,S. G.

Highway, Thaltej, Ahmedabad – 380054.

Gujarat. India.

call-icon+91 79 6157 7000

email-icongeneralqueries@intaspharma.com

© 2019 Intas Pharmaceuticals Ltd.

All rights reserved.